<DOC>
	<DOCNO>NCT02703051</DOCNO>
	<brief_summary>Phase 1 , open-label , parallel , active-controlled , multiple IV dose , proof concept study conduct one study center United States ( US ) .</brief_summary>
	<brief_title>A Study Evaluate PK , Safety Tolerability GMI-1271 With Without Filgrastim Healthy Adult Subjects</brief_title>
	<detailed_description />
	<mesh_term>Lenograstim</mesh_term>
	<criteria>1 . Healthy adult male and/or female , 19 60 year age , inclusive . 2 . Medically healthy clinically significant screen result deem PI . 1 . History presence clinically significant medical condition disease opinion PI . 2 . Alcoholism drug abuse . 3 . Liver disease . 4 . Female subject pregnant lactating . 5 . Known history evidence active hepatitis A , B , C HIV . 6 . Clinically significant cardiovascular disease . 7 . Participation another clinical trial within 28 day prior first dose GMI1271 filgrastim , whichever occur first .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>